Naomi Fujioka, MD, Christopher A. French, MD, Michael J

Slides:

Advertisements

Similar presentations

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Advertisements

NUT Rearrangement is Uncommon in Human Thymic Epithelial Tumors Iacopo Petrini, MD, Christopher A. French, MD, Arun Rajan, MD, Michael J. Cameron, MSC,

Frances A Shepherd, MD, Rafael Rosell, MD Journal of Thoracic Oncology

Cytogenetic and molecular events in adenoma and well-differentiated thyroid follicular- cell neoplasia Paola Caria, Roberta Vanni Cancer Genetics and.

Primary Mucoepidermoid Carcinoma of the Esophagus

Detection of ALK Gene Rearrangement in Non-small Cell Lung Cancer: A Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization.

Detection of Rearrangements and Transcriptional Up-Regulation of ALK in FFPE Lung Cancer Specimens Using a Novel, Sensitive, Quantitative Reverse Transcription.

The 2015 World Health Organization Classification of Lung Tumors

Next-Generation Sequencing Identifies and Immunohistochemistry Confirms a Novel Crizotinib-Sensitive ALK Rearrangement in a Patient with Metastatic Non–Small-Cell.

Heterogeneity of Anaplastic Lymphoma Kinase Gene Rearrangement in Non–Small-Cell Lung Carcinomas: A Comparative Study Between Small Biopsy and Excision.

Transformation to Sarcomatoid Carcinoma in ALK-Rearranged Adenocarcinoma, Which Developed Acquired Resistance to Crizotinib and Received Subsequent Chemotherapies

FISH Analysis of Crizotinib Target Genes ROS1/ALK/MET in Malignant Mesothelioma Sandra Salvi, PhD, Serena Varesano, PhD, Simona Boccardo, PhD, Jean Louis.

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

The Development of a Multitarget, Multicolor Fluorescence in Situ Hybridization Assay for the Detection of Urothelial Carcinoma in Urine Irina A. Sokolova,

Anja C. Roden, MD, Patricia T. Greipp, DO, Darlene L. Knutson, Sara M

Increased ALK Gene Copy Number and Amplification are Frequent in Non-small Cell Lung Cancer Marta Salido, MSc, Lara Pijuan, MD, PhD, Luz Martínez-Avilés,

Bob T. Li, M. B. B. S. , MPH, Dara S. Ross, MD, Dara L

Loss of Phosphatase and Tensin Homolog Protein Expression Is an Independent Poor Prognostic Marker in Lung Adenocarcinoma Naoki Yanagawa, MD, PhD, Charles.

Primary Pulmonary NUT Midline Carcinoma: Clinical, Radiographic, and Pathologic Characterizations Lynette M. Sholl, MD, Mizuki Nishino, MD, Saraswati.

MET and EGFR Mutations Identified in ALK-Rearranged Pulmonary Adenocarcinoma: Molecular Analysis of 25 ALK-Positive Cases Jennifer M. Boland, MD, Jin.

Bright-Field Dual-Color Chromogenic In Situ Hybridization for Diagnosing Echinoderm Microtubule-Associated Protein-Like 4-Anaplastic Lymphoma Kinase-Positive.

Interpretation of Anti-ALK Immunohistochemistry Results

A Case of Large-Cell Neuroendocrine Carcinoma Harboring an EML4–ALK Rearrangement with Resistance to the ALK Inhibitor Crizotinib Naoki Omachi, MD, Shigeki.

Comprehensive Hybrid Capture–Based Next-Generation Sequencing Identifies a Double ALK Gene Fusion in a Patient Previously Identified to Be False-Negative.

ALK and NRG1 Fusions Coexist in a Patient with Signet Ring Cell Lung Adenocarcinoma Lucia Anna Muscarella, PhD, Domenico Trombetta, PhD, Federico Pio.

A Case of Squamous Cell Carcinoma Harboring an EML4-ALK Rearrangement that Was Unsuccessfully Treated with the ALK Inhibitor Alectinib Akihiro Tamiya,

Dual IHC and FISH Testing for ALK Gene Rearrangement in Lung Adenocarcinomas in a Routine Practice: A French Study Anne McLeer-Florin, PhD, Denis Moro-Sibilot,

Combined Use of ALK Immunohistochemistry and FISH for Optimal Detection of ALK- Rearranged Lung Adenocarcinomas Lynette M. Sholl, MD, Stanislawa Weremowicz,

ALK/EML4 Fusion Gene May Be Found in Pure Squamous Carcinoma of the Lung Anna Caliò, MD, Alessia Nottegar, MD, Eliana Gilioli, MD, Emilio Bria, MD, Sara.

Primary Mucoepidermoid Carcinoma of the Esophagus

Deregulation of p27 and Cyclin D1/D3 Control Over Mitosis Is Associated with Unfavorable Prognosis in Non-small Cell Lung Cancer, as Determined in 405.

ALK Rearrangement Detected in a Focus of Pulmonary Atypical Adenomatous Hyperplasia Filippo Lococo, MD, Alessandra Bisagni, MD, Maria Cecilia Mengoli,

Searching for ROS1 Rearrangements in Lung Cancer by Fluorescent In Situ Hybridization: The Importance of Probe Design Arnaud Uguen, MD, Pascale Marcorelles,

A Novel EML4-ALK Variant: Exon 6 of EML4 Fused to Exon 19 of ALK

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

STAT3, Cten, and lung cancer: Simultaneous excitement and caution

Elizabeth B. Gottlin, PhD, Rex C. Bentley, MD, Michael J

Parallel FISH and Immunohistochemical Studies of ALK Status in 3244 Non–Small-Cell Lung Cancers Reveal Major Discordances Florian Cabillic, PharMD, PhD,

Role of Chromosome 3q Amplification in Lung Cancer

NUT Midline Carcinoma: An Aggressive Intrathoracic Neoplasm

High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer Heounjeong Go, MD, Yoon Kyung Jeon, MD, PhD, Hyo Jin.

A Comprehensive Analysis of p16 Expression, Gene Status, and Promoter Hypermethylation In Surgically Resected Non-small Cell Lung Carcinomas William.

Response to Crizotinib Observed in Lung Adenocarcinoma with MET Copy Number Gain but without a High-Level MET/CEP7 Ratio, MET Overexpression, or Exon.

Erratum Journal of Thoracic Oncology

NUT Rearrangement is Uncommon in Human Thymic Epithelial Tumors

Arnaud Uguen, MD, PhD Journal of Thoracic Oncology

Rapid Response to Trastuzumab Emtansine in a Patient with HER2-Driven Lung Cancer Daniela Weiler, MD, Joachim Diebold, MD, Klaus Strobel, MD, Stefan.

High MET Receptor Expression But Not Gene Amplification in ALK 2p23 Rearrangement Positive Non–Small-Cell Lung Cancer Yan Feng, MD, Eugen C. Minca, MD,

Loss of p16INK4A Expression and Homozygous CDKN2A Deletion Are Associated with Worse Outcome and Younger Age in Thymic Carcinomas Scott W. Aesif, MD,

Prognostic Impact of Node Involvement Pattern in Pulmonary pN1 Squamous Cell Carcinoma Patients Masayuki Nakao, MD, Junji Yoshida, MD, PhD, Genichiro.

Vamsidhar Velcheti, MD Journal of Thoracic Oncology

Tracheal Mucoepidermoid Carcinoma

Amplification of MET in a Patient with Malignant Pleural Mesothelioma

Detection of ALK-Positive Non–Small-Cell Lung Cancers on Cytological Specimens: High Accuracy of Immunocytochemistry with the 5A4 Clone Spasenija Savic,

ALK Translocation in Non-small Cell Lung Cancer with Adenocarcinoma and Squamous Cell Carcinoma Markers Samuel J. Klempner, MD, David W. Cohen, MD, Daniel.

Osimertinib for Epidermal Growth Factor Receptor Mutation–Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma Naoyuki.

Toni-Maree Rogers, BMLS, Prudence A

A Rare Case of Endobronchial Amelanotic Melanoma

Immunohistochemistry is a Reliable Screening Tool for Identification of ALK Rearrangement in Non–Small-Cell Lung Carcinoma and is Antibody Dependent

Concomitant Epidermal Growth Factor Receptor Mutation and EML4-ALK Fusion in a Patient with Multifocal Lung Adenocarcinomas Jun Fan, MD Journal of Thoracic.

Biclonal Non-small Cell Lung Cancer in Disseminated Tumor Cells and Tissue Anna Puggina, MSc, Verena Kümmerlen, MD, Korinna Jöhrens-Leder, MD, Ulrich.

Genetic Changes in Squamous Cell Lung Cancer: A Review

Clinical Implications of Variant ALK FISH Rearrangement Patterns

International Thymic Malignancies Interest Group: A Way Forward

EGFR Mutations in Squamous Cell Lung Cancer in Never-Smokers

Neal S Goldstein, MD The Annals of Thoracic Surgery

FGFR1 Amplification in Squamous Cell Carcinoma of The Lung

ALK Status Testing in Non–Small-Cell Lung Carcinoma by FISH on ThinPrep Slides with Cytology Material Eugen C. Minca, MD, PhD, Christopher P. Lanigan,

ALK Gene Rearrangements: A New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung Cancer Benjamin Solomon, MBBS, PhD, Marileila.

Presentation transcript:

Long-Term Survival of a Patient with Squamous Cell Carcinoma Harboring NUT Gene Rearrangement Naomi Fujioka, MD, Christopher A. French, MD, Michael J. Cameron, BSc, Robert A. Kratzke, MD Journal of Thoracic Oncology Volume 5, Issue 10, Pages 1704-1705 (October 2010) DOI: 10.1097/JTO.0b013e3181ebaa20 Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Hematoxylin and eosin staining of squamous cell carcinoma from the bronchus and lung. Portions of the tumor appeared to be well-differentiated squamous cell carcinoma (arrows), consistent with previous reports of nuclear protein of the testis (NUT) variants. BRD4-NUT tumors tend to exhibit less squamous differentiation. Journal of Thoracic Oncology 2010 5, 1704-1705DOI: (10.1097/JTO.0b013e3181ebaa20) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Immunohistochemistry using a monoclonal antibody against nuclear protein of the testis (NUT). NUT midline carcinomas (NMCs) demonstrate diffuse speckled nuclear staining (arrows). This antibody has a sensitivity of 87% and specificity of 100% for NMCs.4 Journal of Thoracic Oncology 2010 5, 1704-1705DOI: (10.1097/JTO.0b013e3181ebaa20) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Dual-color, split-apart fluorescent in situ hybridization for nuclear protein of the testis (NUT) gene rearrangement. The green and red probes flank the 15q14 NUT break point, and the signals are separated in NUT rearrangements (arrows). The most common NUT rearrangement is fusion of BRD4 on chromosome 19 to NUT on chromosome 15 forming the BRD4-NUT fusion gene. NUT variants form fusions with genes other than BRD4, including the highly homologous gene BRD3.2 Journal of Thoracic Oncology 2010 5, 1704-1705DOI: (10.1097/JTO.0b013e3181ebaa20) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions